Study of 28,360 #PsA pts shows blacks have signif more HTN (59 v 52%), DM (31 v 23%), obesity (47 v 30%), gout (12 v 8%); while whites have more cancer (20 v 16%), anxiety (28 v 23%) & OP (14 v 12). Rx (NSAIDs, TNFi, DMARDs) also unequal by race. https://t.co/Ok7vhTdS8g https://t.co/ozFIg9HNuy

• https://bit.ly/42WjRUn

Arborviral infx w/ rituximab? 21 RTX pts dx w/ arboviral neuroinvasive Dz, (encephalitis, acute flaccid myelitis); 79% died. B cell depletion impairs immunity & spread of West Nile Virus, serologic Ab Dx tests; thus if suspected, order RT-PCR tests https://t.co/yQiXI2IYqd https://t.co/dZX2CQJs0L

• https://wb.md/3qX08GG

Small study 57 EGPA pts shows using MTX or AZA to be equipotent as 1st or 2nd line therapy in EGPA. MTX pts used more cumulative steroids (6 g vs 10.7 g @5 yrs) & more AE (66% vs 30%); AZA had fewer asthma/ENT relapses (23% vs 64%, p= 0.04) https://t.co/WZHudojrzk https://t.co/X6xITcQtCw

• https://bit.ly/43Mw4w9

Predictors of DAPSA28 remission in #PsA starting 1st TNF-inhibitor (13 369 bio-naive pts from 13 Euro registries) showed 6 mo remission 25% and 12 retention 63%. Remission predictors: younger age, Dz duration, males (OR 1.85), CRP >10 (OR 1.52) https://t.co/cTefy6xeUB https://t.co/b2Ok6HJgE1

• https://bit.ly/3p3hvFq

HRT for RA? Not Yet Dr. Aurelie Najm discusses OP0268 presented at EULAR 2023 in Milan, Italy. @AurelieRheumo https://t.co/hoyZ2Ezn4G https://t.co/XWfE1RHwpi

• https://bit.ly/3PtetVo

Abatacept Safety Outcomes Across 7 European Registries A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy. https://t.co/XcOSLTgQVR https://t.co/ZfwAA0baRM

• https://bit.ly/3N8dA1K

2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA. https://t.co/5WoIm8OPZs https://t.co/xqNxDvuymJ

• https://bit.ly/3NAo3Vm

RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available. https://t.co/0dV23VPDQH https://t.co/HfKhji40vU

• https://bit.ly/3Jo1bWq

Watch: Should you Assess Rheumatoid Factor Serially? Dr. Jack Cush discusses abstract OP0272 at EULAR 2023 in Milan, Italy. https://t.co/5e4SiPGDUM https://t.co/CzE597Auwg

• https://bit.ly/43OJ3NR

Watch: De Novo Renal Nephritis Flares During Belimumab Trials Drs. Yuz Yusof and Iaonnis Parodis discuss abstract POS1156 at EULAR 2023 in Milan, Italy. https://t.co/XLzDF2VZ7Q https://t.co/iE16Ag3Rsu

• https://bit.ly/3CCubWF

How Often Do You Monitor MTX? Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening. https://t.co/niPFjQTenh https://t.co/JyL8t6EexT

• https://bit.ly/3CUTNyt

Pediatric Rheumatologist Loan assistance repayment program from HSRA. A loan assistance of up to $100,000 to eligible pediatric medical subspecialists in exchange for a 3-year, full-time service commitment at an approved facility in an underserved area https://t.co/6oFkEEKAY9

• https://bit.ly/3PnGGgr